CD274 and non-small cell lung carcinoma: According to the LIPI score, 466 patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors or standard chemotherapy were classified into three prognostic groups (good, intermediate, and poor) based on LDH and dNLR levels.